Collectively, these findings indicate that integrating multiple placental protein biomarkers—such as PP13, PAPP-A, AFP, ANXA2, and GDF-15—with angiogenic factors like sFlt-1 and PlGF could substantially improve the early prediction and risk stratification of preeclampsia. This evidence concerns the gene PAPPA and preeclampsia.